HSCT is also limited in efficacy, due to immune-suppressive comedications that aim at controlling GvHD: 40% of post-HSCT AML patients relapse, with a dismal prognosis of 2-year survival less than 20%.

Steroid-refractory acute GvHD is a serious and life-threatening condition that can occur as a complication of donor haematopoietic stem cell transplantation (HSCT), used to treat blood cancers and ...

Orencia (abatacept) becomes the first drug to be approved to prevent GvHD, a condition in which donor immune cells attack tissues in the patient receiving an HSCT, commonly known as a bone marrow ...

While gene therapy has emerged as a promising alternative for treating beta-thalassemia, hematopoietic stem cell transplantation (HSCT ... versus-host disease (GVHD), he added, "mainly due ...